Lupin acquires specialty portfolio from German company

25 Jul 2015 Evaluate

Pharma Major Lupin has entered into a strategic asset purchase agreement with Temmler Pharma  Gmbh & CO. KG (Temmler), a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler’s specialty product portfolio subject to certain closing conditions.

Based in Marburg (Germany), Temmler has a fast growing specialty portfolio of 13 products including key Central Nervous System (CNS) products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease as well as fast-growing dermatology products for anti-wart treatment. Since Huntington disease has many symptoms ranging from motoric symptoms to personality changes, both Temmler and Hormosan products can be used to treat the disease.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.

 

Lupin Share Price

2125.70 -21.90 (-1.02%)
28-Jan-2026 10:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1616.00
Dr. Reddys Lab 1225.30
Cipla 1321.90
Zydus Lifesciences 887.90
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×